Moderna (Brazil) Top Management
M1RN34 Stock | BRL 12.57 0.69 5.81% |
Moderna employs about 3.7 K people. The company is managed by 10 executives with a total tenure of roughly 8634 years, averaging almost 863.0 years of service per executive, having 370.0 employees per reported executive. Analysis of Moderna's management performance can provide insight into the company performance.
Shannon Klinger Insider Chief Sec |
James Mock Insider Chief Officer |
Moderna |
Moderna Management Team Effectiveness
The company has return on total asset (ROA) of 0.3526 % which means that it generated a profit of $0.3526 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.8369 %, meaning that it generated $0.8369 on every $100 dollars invested by stockholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities.Moderna Workforce Comparison
Moderna is considered to be number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 237,525. Moderna claims roughly 3,700 in number of employees contributing just under 2% to stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.55 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.62 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.62. Moderna Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Moderna Price Series Summation is a cross summation of Moderna price series and its benchmark/peer.
Moderna Notable Stakeholders
A Moderna stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Moderna often face trade-offs trying to please all of them. Moderna's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Moderna's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Shannon Klinger | Chief Sec | Profile | |
James Mock | Chief Officer | Profile | |
Stephane Bancel | CEO Director | Profile | |
John Reynders | Chief Officer | Profile | |
Jerh Collins | Chief Officer | Profile | |
Lavina CFA | VP Relations | Profile | |
Juan Andres | Pres Expansion | Profile | |
Melissa Moore | Chief Board | Profile | |
Noubar Afeyan | Independent CoFounder | Profile | |
Stephen MD | President | Profile |
About Moderna Management Performance
The success or failure of an entity such as Moderna often depends on how effective the management is. Moderna management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Moderna management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Moderna management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. MODERNA INC operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 1800 people.
Please note, the presentation of Moderna's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moderna's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Moderna's management manipulating its earnings.
Moderna Workforce Analysis
Traditionally, organizations such as Moderna use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Moderna within its industry.Moderna Manpower Efficiency
Return on Moderna Manpower
Revenue Per Employee | 5M | |
Revenue Per Executive | 1.8B | |
Net Income Per Employee | 3.3M | |
Net Income Per Executive | 1.2B |
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Stocks Directory Find actively traded stocks across global markets | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |